Gregory M Vercellotti

List of Publications by Year
in descending order

180	8,534	71102 41	46799 89
papers	citations	h-index	g-index

181	181	181	8577
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood, 2013, 121, 1276-1284.	1.4	582
2	Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood, 2014, 123, 377-390.	1.4	555
3	Pro-oxidant and cytotoxic effects of circulating heme. Blood, 2002, 100, 879-887.	1.4	549
4	Carbon Monoxide Generated by Heme Oxygenase-1 Suppresses the Rejection of Mouse-to-Rat Cardiac Transplants. Journal of Immunology, 2001, 166, 4185-4194.	0.8	440
5	Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood, 2000, 96, 2451-2459.	1.4	301
6	Carbon Monoxide Expedites Metabolic Exhaustion to Inhibit Tumor Growth. Cancer Research, 2013, 73, 7009-7021.	0.9	295
7	INHIBITION OF COMPLEMENT-MEDIATED ENDOTHELIAL CELL CYTOTOXICITY BY DECAY-ACCELERATING FACTOR. Transplantation, 1991, 52, 530-533.	1.0	246
8	Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance. Journal of Infectious Diseases, 1995, 171, 576-583.	4.0	243
9	Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. British Journal of Haematology, 1995, 91, 403-408.	2.5	236
10	Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. Journal of Clinical Investigation, 2006, 116, 808-816.	8.2	233
11	Red Cells, Hemoglobin, Heme, Iron, and Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1347-1353.	2.4	200
12	Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 2000, 96, 314-320.	1.4	198
13	Heme Degradation and Vascular Injury. Antioxidants and Redox Signaling, 2010, 12, 233-248.	5.4	196
14	Transgenic sickle mice have vascular inflammation. Blood, 2003, 101, 3953-3959.	1.4	195
15	Heme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-1. Kidney International, 2001, 59, 106-117.	5.2	194
16	Infection and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1417-1420.	2.4	181
17	Heme, Heme Oxygenase, and Ferritin: How the Vascular Endothelium Survives (and Dies) in an Iron-Rich Environment. Antioxidants and Redox Signaling, 2007, 9, 2119-2138.	5.4	174
18	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Advances, 2019, 3, 1970-1980.	5.2	164

#	Article	IF	Citations
19	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. Journal of Clinical Oncology, 2014, 32, 3264-3274.	1.6	146
20	Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nature Reviews Drug Discovery, 2019, 18, 139-158.	46.4	116
21	Bloodâ€“Nanoparticle Interactions and in Vivo Biodistribution: Impact of Surface PEG and Ligand Properties. Molecular Pharmaceutics, 2012, 9, 2146-2155.	4.6	113
22	Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate. Antioxidants and Redox Signaling, 2017, 26, 748-762.	5.4	95
23	The endothelial biology of sickle cell disease. Translational Research, 1997, 129, 288-293.	2.3	94
24	Heme protein-mediated renal injury: A protective role for 21-aminosteroids in vitro and in vivo. Kidney International, 1995, 47, 592-602.	5.2	93
25	Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome. Journal of Clinical Oncology, 2009, 27, 3634-3641.	1.6	92
26	Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction. PLoS ONE, 2018, 13, e0196455.	2.5	88
27	INTERCELLULAR ADHESION MOLECULE-1 EXPRESSION IN ENDOTHELIAL CELLS IS ACTIVATED BY CYTOMEGALOVIRUS IMMEDIATE EARLY PROTEINS1. Transplantation, 1999, 67, 137-144.	1.0	79
28	Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. Journal of Molecular Medicine, 2010, 88, 665-675.	3.9	77
29	The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood, 2010, 115, 2483-2490.	1.4	76
30	Regulation of Heme Oxygenase-1 Protein Expression by miR-377 in Combination with miR-217. Journal of Biological Chemistry, 2011, 286, 3194-3202.	3.4	76
31	Heme and the Endothelium. Journal of Biological Chemistry, 1998, 273, 23388-23397.	3.4	71
32	Ibuprofen inhibits granulocyte responses to inflammatory mediators. Inflammation, 1984, 8, 33-44.	3.8	69
33	Microvascular blood flow and stasis in transgenic sickle mice: Utility of a dorsal skin fold chamber for intravital microscopy. American Journal of Hematology, 2004, 77, 117-125.	4.1	67
34	Iron and Atherosclerosis: Inhibition by the Iron Chelator Deferiprone (L1). Journal of Surgical Research, 1997, 73, 35-40.	1.6	61
35	Supression of hemin-mediated oxidation of low-density lipoprotein and subsequent endothelial reactions by hydrogen sulfide (H2S). Free Radical Biology and Medicine, 2009, 46, 616-623.	2.9	56
36	Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biology of Blood and Marrow Transplantation, 2015, 21, 1029-1036.	2.0	53

#	Article	IF	Citations
37	Critical role of C5a in sickle cell disease. American Journal of Hematology, 2019, 94, 327-337.	4.1	48
38	Hemoglobin oxidationâ€“dependent reactions promote interactions with band 3 and oxidative changes in sickle cellâ€“derived microparticles. JCI Insight, 2018, 3, .	5.0	48
39	The multifaceted role of ischemia/reperfusion in sickle cell anemia. Journal of Clinical Investigation, 2020, 130, 1062-1072.	8.2	48
40	Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%. Critical Care Medicine, 1984, 12, 428-431.	0.9	47
41	Historical perspective and clinical implications of the Pelgerâ€Huet cell. American Journal of Hematology, 2009, 84, 116-119.	4.1	47
42	Vasculotoxic and Proinflammatory Effects of Plasma Heme: Cell Signaling and Cytoprotective Responses. ISRN Oxidative Medicine, 2013, 2013, 1-9.	0.8	46
43	Hepatic Overexpression of Hemopexin Inhibits Inflammation and Vascular Stasis in Murine Models of Sickle Cell Disease. Molecular Medicine, 2016, 22, 437-451.	4.4	45
44	Haptoglobin attenuates hemoglobin-induced heme oxygenase-1 in renal proximal tubule cells and kidneys of a mouse model of sickle cell disease. Blood Cells, Molecules, and Diseases, 2015, 54, 302-306.	1.4	40
45	Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. Translational Research, 2005, 145, 204-211.	2.3	39
46	A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica, 2020, 105, 623-631.	3.5	39
47	Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs. American Heart Journal, 1990, 120, 510-520.	2.7	38
48	The White platelet syndrome: a new autosomal dominant platelet disorderI. Structural abnormalities. Platelets, 2004, 15, 173-184.	2.3	38
49	Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia. PLoS ONE, 2018, 13, e0205194.	2.5	37
50	THERAPEUTIC RAMIFICATIONS OF THE INTERACTION OF COMPLEMENT, GRANULOCYTES, AND PLATELETS IN THE PRODUCTION OF ACUTE LUNG INJURY. Annals of the New York Academy of Sciences, 1982, 384, 489-495.	3.8	36
51	Pre-conditioning cryosurgery: Cellular and molecular mechanisms and dynamics of TNF-Î± enhanced cryotherapy in an in vivo prostate cancer model system. Cryobiology, 2010, 61, 280-288.	0.7	35
52	Iron deficiency and diffuse nonscarring scalp alopecia in women: More pieces to the puzzle. Journal of the American Academy of Dermatology, 2010, 63, 1070-1076.	1.2	34
53	The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vasoâ€occlusive crises. American Journal of Hematology, 2017, 92, 569-582.	4.1	33
54	Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2011, 17, 1025-1032.	2.0	32

#	Article	IF	Citations
55	H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice. Frontiers in Pharmacology, 2014, 5, 79.	3.5	32
56	Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease. Blood, 2020, 135, 1783-1787.	1.4	32
57	Endothelial Activation and the Kidney: Vasomediator Modulation and Antioxidant Strategies. American Journal of Kidney Diseases, 1993, 21, 331-343.	1.9	31
58	Tumor necrosis factor-Î±â€“induced accentuation in cryoinjury: mechanisms in vitro and in vivo. Molecular Cancer Therapeutics, 2008, 7, 2547-2555.	4.1	31
59	Serum haptoglobin and hemopexin levels are depleted in pediatric sickle cell disease patients. Blood Cells, Molecules, and Diseases, 2018, 72, 34-36.	1.4	31
60	Role of TLR4 signaling in the nephrotoxicity of heme and heme proteins. American Journal of Physiology - Renal Physiology, 2018, 314, F906-F914.	2.7	31
61	Immunological Biocompatibility in Blood Substitutes. International Anesthesiology Clinics, 1985, 23, 47-62.	0.8	29
62	Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia. Blood, 2019, 134, 3544-3544.	1.4	29
63	Human cytomegalovirus immediate early proteins upregulate endothelial p53 function. FEBS Letters, 2000, 474, 213-216.	2.8	28
64	Cytomegalovirus inhibits p53 nuclear localization signal function. Journal of Molecular Medicine, 2001, 78, 642-647.	3.9	28
65	A Microassay to Assess the Oxidative Resistance of Low-Density Lipoproteins. Clinical Chemistry, 1998, 44, 1762-1764.	3.2	27
66	The Fucosylation Inhibitor, 2-Fluorofucose, Inhibits Vaso-Occlusion, Leukocyte-Endothelium Interactions and NF-Ä¸B Activation in Transgenic Sickle Mice. PLoS ONE, 2015, 10, e0117772.	2.5	27
67	Identification of a Heme Activation Site on the MD-2/TLR4 Complex. Frontiers in Immunology, 2020, 11, 1370.	4.8	26
68	Overview of infections and cardiovascular diseasesâ˜†â˜†â˜†. Journal of Allergy and Clinical Immunology, 2001, 108, S117-S120.	2.9	24
69	Bronchiolitis obliterans after bone marrow transplantation. American Journal of Hematology, 1985, 18, 325-328.	4.1	23
70	A monocyteâ€TNFâ€endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade. American Journal of Hematology, 2017, 92, 1119-1130.	4.1	23
71	Vasculoâ€toxic and proâ€inflammatory action of unbound haemoglobin, haem and iron in transfusionâ€dependent patients with haemolytic anaemias. British Journal of Haematology, 2021, 193, 637-658.	2.5	22
72	Herpes Simplex Virus Decreases Endothelial Cell Plasminogen Activator Inhibitor. Thrombosis and Haemostasis, 1993, 69, 253-258.	3.4	22

#	Article	IF	Citations
73	Interleukin-4 Induces Up-regulation of Endothelial Cell Claudin-5 through Activation of FoxO1. Journal of Biological Chemistry, 2014, 289, 838-847.	3.4	21
74	Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. Blood Advances, 2020, 4, 1284-1295.	5.2	21
75	Prothrombotic phenotype diversity of human aortic endothelial cells in culture. Thrombosis Research, 1992, 67, 135-145.	1.7	20
76	Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease. Frontiers in Immunology, 2020, 11, 613278.	4.8	20
77	Robust Vascular Protective Effect of Hydroxamic Acid Derivatives in a Sickle Mouse Model of Inflammation. Microcirculation, 2006, 13, 489-497.	1.8	19
78	Noncanonical Roles of Caspase-4 and Caspase-5 in Heme-Driven IL-1Î² Release and Cell Death. Journal of Immunology, 2021, 206, 1878-1889.	0.8	19
79	Not simply misshapen red cells: multimolecular and cellular events in sickle vaso-occlusion. Journal of Clinical Investigation, 2014, 124, 1462-1465.	8.2	19
80	Phenotypic Characterization the Townes Sickle Mice. Blood, 2014, 124, 4916-4916.	1.4	19
81	Case series supporting heme detoxification via therapeutic plasma exchange in acute multiorgan failure syndrome resistant to red blood cell exchange in sickle cell disease. Transfusion, 2018, 58, 470-479.	1.6	18
82	Factor V Leiden and hepatic artery thrombosis after liver transplantation. Clinical Transplantation, 2006, 20, 132-135.	1.6	17
83	Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature. Journal of Oncology Pharmacy Practice, 2018, 24, 56-62.	0.9	17
84	High Plasma Erythropoietin Levels are Associated With Prolonged Coma Duration and Increased Mortality in Children With Cerebral Malaria. Clinical Infectious Diseases, 2015, 60, 27-35.	5.8	16
85	Sustained treatment of sickle cell mice with haptoglobin increases <scp>HO</scp>â€1 and Hâ€ferritin expression and decreases iron deposition in the kidney without improvement in kidney function. British Journal of Haematology, 2016, 175, 714-723.	2.5	16
86	Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence. Journal of Clinical Medicine, 2022, 11, 630.	2.4	15
87	Antithrombotic effects of heme-degrading and heme-binding proteins. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H671-H681.	3.2	14
88	A case of VEXAS syndrome associated with EBV-associated hemophagocytic lymphohistiocytosis. Blood Cells, Molecules, and Diseases, 2022, 93, 102636.	1.4	14
89	Î²-Globin Sleeping Beauty Transposon Reduces Red Blood Cell Sickling in a Patient-Derived CD34+-Based In Vitro Model. PLoS ONE, 2013, 8, e80403.	2.5	13
90	Erythroid-Specific Expression of Î²-globin from Sleeping Beauty-Transduced Human Hematopoietic Progenitor Cells. PLoS ONE, 2011, 6, e29110.	2.5	12

#	Article	IF	Citations
91	The endothelial protein C receptor rs867186-GG genotype is associated with increased soluble EPCR and could mediate protection against severe malaria. Scientific Reports, 2016, 6, 27084.	3.3	12
92	Decreased erythrocyte binding of Siglec-9 increases neutrophil activation in sickle cell disease. Blood Cells, Molecules, and Diseases, 2020, 81, 102399.	1.4	11
93	Complement, oxidants, and endothelial injury: how a bedside observation opened a door to vascular biology. Journal of Clinical Investigation, 2012, 122, 3044-3045.	8.2	11
94	A Novel, Highly Potent and Selective PDE9 Inhibitor for the Treatment of Sickle Cell Disease. Blood, 2016, 128, 268-268.	1.4	11
95	Potential role of viruses in thrombosis and atherosclerosis. Trends in Cardiovascular Medicine, 1995, 5, 128-133.	4.9	10
96	<scp>S</scp>trongyloides hyperinfection following hematopoietic stem cell transplant in a patient with <scp>HTLV</scp>â€1â€associated Tâ€cell leukemia. Transplant Infectious Disease, 2017, 19, e12638.	1.7	10
97	Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 2000, 96, 314-320.	1.4	10
98	Updated Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia. Blood, 2021, 138, 3974-3974.	1.4	10
99	ILâ€4 and ILâ€13 induce protection from complement and melittin in endothelial cells despite initial loss of cytoplasmic proteins: membrane resealing impairs quantifying cytotoxicity with the lactate dehydrogenase permeability assay. Xenotransplantation, 2015, 22, 295-301.	2.8	9
100	Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease. Pain, 2018, 159, 1382-1391.	4.2	9
101	Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, e20-e25.	2.0	9
102	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. Biology of Blood and Marrow Transplantation, 2019, 25, 56-62.	2.0	9
103	Heme oxygenase-2 protects against ischemic acute kidney injury: influence of age and sex. American Journal of Physiology - Renal Physiology, 2019, 317, F695-F704.	2.7	9
104	Protection of porcine endothelial cells against apoptosis with interleukinâ€4. Xenotransplantation, 2011, 18, 343-354.	2.8	8
105	Soluble MD-2 and Heme in Sickle Cell Disease Plasma Promote Pro-Inflammatory Signaling in Endothelial Cells. Frontiers in Immunology, 2021, 12, 632709.	4.8	8
106	Heme Potently Stimulates Tissue Factor Expression By Peripheral Blood Monocytes: A Novel Mechanism For Thrombosis In Intravascular Hemolytic Diseases. Blood, 2013, 122, 2215-2215.	1.4	8
107	Serum Haptoglobin and Hemopexin Levels in Pediatric SS and SC Disease Patients: Biomarker of Hemolysis and Inflammation. Blood, 2016, 128, 3649-3649.	1.4	8
108	Multiple inducers of endothelial <scp>NOS</scp> (<scp>eNOS</scp>) dysfunction in sickle cell disease. American Journal of Hematology, 2021, 96, 1505-1517.	4.1	7

#	Article	IF	Citations
109	Plasma Hemoglobin and Heme Trigger Weibel Palade Body Exocytosis and Vaso-Occlusion in Transgenic Sickle Mice. Blood, 2011, 118, 896-896.	1.4	7
110	SARS-CoV-2 severity in African Americans â€“ A role for Duffy Null?. Haematologica, 2020, 105, 2892.	3.5	7
111	Special delivery: microparticles convey heme. Blood, 2015, 125, 3677-3678.	1.4	6
112	Interference With TNFÎ± Using Long-Term Etanercept In S+SAntilles Sickle Transgenic Mice Ameliorates Abnormal Endothelial Activation, Vasoocclusion, and Pulmonary Hypertension Including Its Pulmonary Arterial Wall Remodeling. Blood, 2013, 122, 728-728.	1.4	6
113	Complement Activation in a Murine Model of Sickle Cell Disease: Inhibition of Vaso-Occlusion By Blocking C5 Activation. Blood, 2016, 128, 158-158.	1.4	6
114	A â€˜touchâ€™ of the White platelet syndrome. Platelets, 2005, 16, 346-361.	2.3	5
115	Selective Enhancement of Contractions to Î±1-adrenergic Receptor Activation in the Aorta of Mice With Sickle Cell Disease. Journal of Cardiovascular Pharmacology, 2011, 57, 263-266.	1.9	5
116	De novo CD5â€positive primary cardiac diffuse large Bâ€cell lymphoma diagnosed by pleural fluid cytology. Diagnostic Cytopathology, 2014, 42, 259-267.	1.0	5
117	Impermeant stilbene disulfonic acids block chemotactic peptide receptor function on human granulocytes. Inflammation, 1989, 13, 31-45.	3.8	4
118	Intravenous immunoglobulin for treatment of necrobiotic xanthogranuloma. Dermatologic Therapy, 2019, 32, e12744.	1.7	4
119	Renal Functional Decline in Sickle Cell Disease and Trait. Journal of the American Society of Nephrology: JASN, 2020, 31, 236-238.	6.1	4
120	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer Journal, 2021, 11, 96.	6.2	4
121	Haptoglobin and Hemopexin Infusion Efficiently Activates the Nrf2/HO-1 Axis and Inhibits Inflammation and Vaso-Occlusion in Murine Sickle Cell Disease. Blood, 2016, 128, 2477-2477.	1.4	4
122	Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd. Blood, 2021, 138, 261-261.	1.4	4
123	Isolated relapse of acute myelogenous leukemia presenting as a gastric ulcer. American Journal of Hematology, 1991, 37, 270-273.	4.1	3
124	PlGF: a link between inflammation and angiogenesis in sickle disease. Blood, 2003, 102, 1153-1153.	1.4	3
125	Clonal Lymphoproliferations in a Patient With Common Variable Immunodeficiency. Laboratory Medicine, 2016, 47, 318-325.	1.2	3
126	Elevated systemic heme and iron levels as risk factor for vascular dysfunction and atherosclerosis: Evidence from a beta-thalassemia cohort study. Atherosclerosis, 2017, 263, e107-e108.	0.8	3

#	Article	IF	Citations
127	Evidence for complement-mediated bone marrow necrosis in a young adult with sickle cell disease. Blood Cells, Molecules, and Diseases, 2021, 86, 102508.	1.4	3
128	Ruxolitinib Reduces Endothelial Pro-Adhesive Interactions: Implications for JAK2V617+ MPN Thrombosis. Blood, 2020, 136, 1-1.	1.4	3
129	Oxidative Stress and Vaso-Occlusion in Sickle Cell Disease: Role of Activated Leukocytes and Redox Active Iron.. Blood, 2005, 106, 3165-3165.	1.4	3
130	Hemoglobin S Oxidation Promotes Plasma-Derived Microparticle Membrane Alterations and Toxicity. Blood, 2016, 128, 856-856.	1.4	3
131	Association between Sensorineural Hearing Loss and Homozygous Sickle Cell Anemia: A Meta-Analysis. Blood, 2019, 134, 3453-3453.	1.4	3
132	ML-0207/ASP8731: A Novel BACH1 Inhibitor That Induces Fetal Hemoglobin in Treatment of Sickle Cell Disease. Blood, 2021, 138, 854-854.	1.4	3
133	Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia. Blood Cells, Molecules, and Diseases, 2019, 77, 109-112.	1.4	2
134	Case report of an unusual presentation of Staphylococcus aureus induced toxic shock syndrome/hyperimmunoglobulinemia E syndrome. Medicine (United States), 2020, 99, e19746.	1.0	2
135	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. Blood, 2018, 132, 71-71.	1.4	2
136	Thiocyanate Blocks Peroxidase-Dependent Extracellular Trap (ET) Formation By PMN and Eosinophils: Heme Is a Potent New Agonist For The ET Pathway. Blood, 2013, 122, 323-323.	1.4	2
137	Dimethyl Fumarate Induces Cytoprotection and Inhibits Inflammation and Vaso-Occlusion in Transgenic Sickle Mice. Blood, 2014, 124, 219-219.	1.4	2
138	Inhaled Carbon Monoxide: An Anti-Inflammatory Modulator in Transgenic Sickle Mice.. Blood, 2007, 110, 2268-2268.	1.4	2
139	ABO Mismatch Adversely Affects GvHD In Recipients of HLA Matched Unrelated Marrow or Peripheral Blood but Not Single or Double Umbilical Cord Blood Transplants. Blood, 2010, 116, 226-226.	1.4	2
140	Systemic Heme and Iron Overload Results in Depletion of Serum Hemopexin, Haptoglobin and Transferrin and Correlates with Markers of Endothelial Activation and Lipid Oxidation in Beta Thalassemia Major and Intermedia. Blood, 2016, 128, 2469-2469.	1.4	2
141	Reply to Eisenhut. Clinical Infectious Diseases, 2015, 60, 1138-9.	5.8	1
142	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (PregnylÂ®): A Phase I Study. Biology of Blood and Marrow Transplantation, 2019, 25, S240-S241.	2.0	1
143	Deletion of TLR4 in Townes SS Mice Prevents Microvascular Stasis in Response to Hemin, LPS and Hypoxia/Reoxygenation: Role of Inflammation. Blood, 2019, 134, 3555-3555.	1.4	1
144	Heme Oxygenase-1: A Potential Modulator of Inflammation and Vaso-Occlusion in Sickle Cell Disease.. Blood, 2004, 104, 365-365.	1.4	1

#	Article	IF	Citations
145	Polynitroxyl Albumin Prevents Vaso-Occlusion in Transgenic Sickle Mice.. Blood, 2004, 104, 366-366.	1.4	1
146	Targeting Putative Mu Opioid/Chemokine Receptor Type 5 Heteromers Potently Attenuates Nociception in a Murine Model of Sickle Cell Disease. Blood, 2015, 126, 277-277.	1.4	1
147	Three Months of Human Haptoglobin Treatment Decreases Iron Deposition in the Kidneys of Townes Sickle Mice. Blood, 2015, 126, 2163-2163.	1.4	1
148	Catheter-Related Thrombosis in Recipients of Autologous Hematopoietic Cell Transplantation (AHCT) with Myeloma and Lymphoma: Risk Factors and Management. Biology of Blood and Marrow Transplantation, 2018, 24, S135-S136.	2.0	0
149	A Simpler Answer â€“ After All This Time. American Journal of Medicine, 2019, 132, e37-e38.	1.5	0
150	Itâ€™s all in the film. British Journal of Haematology, 2020, 189, 8-8.	2.5	0
151	Sepsis Following Parenteral Sodium Ferric Gluconate Complex Infusion: A Report of Two Cases and Literature Review.. Blood, 2006, 108, 3729-3729.	1.4	0
152	Differentiation of Highly Conserved Host and Transgene mRNA in HO-1 Gene Therapy.. Blood, 2007, 110, 2266-2266.	1.4	0
153	The Major Phagocyte Peroxidase-Derived Oxidant, HOSCN (Hypothiocyanous Acid), Induces Proinflammatory and Cytoprotective Gene Expression in Endothelium: A Mechanism for Microlocalized Regulation of Inflammation.. Blood, 2007, 110, 3295-3295.	1.4	0
154	Potential Role of Heme Oxygenase-1 in Arsenic Trioxide and Hemin-Mediated Differentiation of Human Promyelocytic Leukemia Cells. Blood, 2008, 112, 3981-3981.	1.4	0
155	Gene-Specific Effects of the Histone Deacetylase Inhibitor TSA on Activation of a Pro-Inflammatory Endothelial Cell Phenotype by the Major Phagocyte Peroxidase-Derived Oxidant HOSCN.. Blood, 2008, 112, 1274-1274.	1.4	0
156	Carbon Monoxide Decreases Leukocytosis in Murine Sickle Cell Disease Models Via Decreased Granulopoiesis.. Blood, 2008, 112, 1433-1433.	1.4	0
157	Hypocalcemia during Autologous Stem Cell Transplant with Concurrent Biphosphonate Use in Patients with Multiple Myeloma. Blood, 2008, 112, 4335-4335.	1.4	0
158	Heme Oxygenase-1 Gene Therapy in a Murine Model of Sickle Cell Disease.. Blood, 2009, 114, 1527-1527.	1.4	0
159	The HDAC Inhibitors Trichostatin A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA) Exhibit Multiple Modalities of Benefit for the Vascular Pathology of Sickle Disease.. Blood, 2009, 114, 2586-2586.	1.4	0
160	Heme and the Vasculature: How the Endothelium Protects Itself Against Toxic Iron. Blood, 2010, 116, SCI-25-SCI-25.	1.4	0
161	Exhaled Carbon Monoxide as a Marker of Hemolysis In Transgenic Mouse Models of Sickle Cell Anemia.. Blood, 2010, 116, 1642-1642.	1.4	0
162	Carbon Monoxide Therapy Reduces Reactive Oxygen Species Production and the Short-Term Hematopoietic Stem Cell Population In Heme-Oxygenase-1 Knockout Mice. Blood, 2010, 116, 4767-4767.	1.4	0

#	Article	IF	Citations
163	The Blood Monocyte - TNF - Endothelial Axis in Activation of Endothelial Tissue Factor in the Transgenic Sickle Mouse: Possible Relevance of Etanercept to Sickle Coagulopathy. Blood, 2011, 118, 1048-1048.	1.4	0
164	Carbon Monoxide Therapy Modulates Hematopoietic Stem Cell Development in Heme-Oxygenase-1 Knockout Mice. Blood, 2011, 118, 1318-1318.	1.4	0
165	Prevention of Venular Stasis, Circulatory Collapse and Mortality in Transgenic Sickle Mice Administered MP4CO, a Pegylated Hemoglobin Saturated with Carbon Monoxide. Blood, 2011, 118, 850-850.	1.4	0
166	MP4CO, a Pegylated Hemoglobin Saturated with Carbon Monoxide, Inhibits Microvascular Stasis in Transgenic Sickle Mice Through Heme Oxygenase-1.. Blood, 2012, 120, 2112-2112.	1.4	0
167	H-Ferritin Ferroxidase Activity Induces Cytoprotective Pathways and Inhibits Microvascular Stasis in Transgenic Sickle Mice. Blood, 2012, 120, 378-378.	1.4	0
168	Bortezomib Is Highly Effective For Pure Red Cell Aplasia After ABO-Incompatible Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 5495-5495.	1.4	0
169	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood, 2013, 122, 2145-2145.	1.4	0
170	Fucosylation Inhibitor, 2-Fluorofucose, Inhibits NF-Î²B Activation and Vaso-Occlusion In Transgenic Sickle Mice. Blood, 2013, 122, 730-730.	1.4	0
171	Hemopexin Gene Therapy Inhibits Inflammation and Vaso-Occlusion in Transgenic Sickle Cell Mice. Blood, 2015, 126, 412-412.	1.4	0
172	Decreased Erythrocyte Binding Capability for Neutrophil Siglec-9 Is a Source of Oxidative Stress in Sickle Cell Disease. Blood, 2018, 132, 3650-3650.	1.4	0
173	Thrombin-Mediated Activation of PAR-1 Contributes to Microvascular Stasis in Mouse Models of Sickle Cell Disease Via Increased Endothelial Expression of P-Selectin and VWF. Blood, 2018, 132, 266-266.	1.4	0
174	Increased Release of Soluble MD-2 in Sickle Cell Disease and Its Role in Pro-Inflammatory Signaling in Endothelial Cells. Blood, 2019, 134, 208-208.	1.4	0
175	Identification of a Heme Activation Site on the MD-2/TLR4 Complex. Blood, 2019, 134, 209-209.	1.4	0
176	Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis. Blood, 2021, 138, 1811-1811.	1.4	0
177	Synthetic Heparan Sulfate Compounds Attenuate Vascular Complications Associated with Sickle Cell Disease. Blood, 2021, 138, 857-857.	1.4	0
178	Microvascular Stasis Inhibition By Hemopexin in the Townes Mouse Model of Sickle Cell Disease. Blood, 2020, 136, 9-9.	1.4	0
179	Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd. Transplantation and Cellular Therapy, 2022, 28, S58-S59.	1.2	0
180	A Vanishing Cecal Mass: A Rare Gastrointestinal Manifestation of Systemic Mastocytosis. Cureus, 2021, 13, e20784.	0.5	0